The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

OBJECTIVES: Although immune checkpoint inhibitors (ICIs) have been shown to improve overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients, ICIs sometimes cause various types of immune-related adverse events (irAEs), which lead to the interruption of ICI treatment. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujisaki, Toshiya, Watanabe, Satoshi, Ota, Takeshi, Kushiro, Kohei, Sato, Yusuke, Takahashi, Miho, Ohtsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Ichikawa, Kosuke, Hokari, Satoshi, Kondo, Rie, Miyabayashi, Takao, Abe, Tetsuya, Miura, Satoru, Tanaka, Hiroshi, Okajima, Masaaki, Terada, Masaki, Matsumoto, Naoya, Ishida, Takashi, Iwashima, Akira, Sato, Kazuhiro, Yoshizawa, Hirohisa, Aoki, Nobumasa, Hayashi, Masachika, Ohshima, Yasuyoshi, Koya, Toshiyuki, Kikuchi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498597/
https://www.ncbi.nlm.nih.gov/pubmed/34631533
http://dx.doi.org/10.3389/fonc.2021.704475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498597/
https://www.ncbi.nlm.nih.gov/pubmed/34631533
http://dx.doi.org/10.3389/fonc.2021.704475

Ejemplares similares